Edwards Lifesciences

EW

Market cap $45.1B

NEW ORLEANS--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new data on the EVOQUE transcatheter tricuspid valve replacement (TTVR) system at the American College of Cardiology Annual Scientific Session (ACC.26), demonstrating significant and sustained patient benefits including lower mortality when accounting for patient crossover, extending the findings presented at the European Society of Cardiology Congress (ESC 2025). The new TRISCEND II trial data presented today during.

Edwards Lifesciences delivered 11% revenue growth in 2025, driven by robust TAVR and accelerating TMTT businesses. Edwards Lifesciences guides for 8-10% sales growth and adjusted EPS of $2.90-$3.05 in 2026, with TMTT sales expected to rise 40%. Valuation has compressed to 26x forward earnings, supported by a strong net cash position and ongoing share repurchases.

EW shares jump 22.1% in a year as growth in TMTT and strong adoption of PASCAL, EVOQUE and SAPIEN technologies fuel momentum.

Edwards Lifesciences Corporation (EW) Presents at Leerink Global Healthcare Conference 2026 Transcript

Edwards Lifesciences Corporation (EW) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

ISRG, GMED, EW, ALC and IRMD show strong short-term upside as AI tools, acquisitions and new product pipelines fuel growth.

Edwards Lifesciences Corporation (EW) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Edwards Lifesciences Corporation (EW) Presents at Citi's 2026 Unplugged MedTech and Life Sciences Access Day Transcript

IRVINE, Calif.--(BUSINESS WIRE)--At the close of Heart Month, Edwards Lifesciences (NYSE: EW) underscored its leadership in structural heart innovation, advancing care through deep expertise and strong partnerships so people with structural heart disease can live longer, healthier lives. As part of this commitment, Edwards announced the impact and renewed vision for Every Heartbeat Matters, its signature global health initiative, to help 2 million more patients facing barriers worldwide access.

ISRG, EW and ELMD tap GenAI to enhance diagnostics and workflows, even as MedTech faces cost pressures, data risks and macro headwinds.